CR665

Opioid Peptide / Kappa Opioid Receptor AgonistRx: ResearchCompound: Research

Also known as: CR 665, FE200665

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

CR665 (also known as FE200665) is a peripherally restricted, selective kappa-opioid receptor agonist peptide developed to provide analgesia with reduced CNS-mediated adverse effects. It has been investigated in preclinical and early clinical studies for pain management, particularly visceral and inflammatory pain, without the psychotomimetic effects associated with centrally acting kappa agonists.

Mechanism of Action

Selective peripheral kappa-opioid receptor (KOR) agonist; binds kappa-opioid receptors in peripheral tissues without crossing the blood-brain barrier, thereby producing analgesia without centrally mediated side effects such as dysphoria or sedation.

Routes of Administration

IntravenousSubcutaneous

Goals & Uses

  • Pruritus (itch) modulationSymptom ManagementLow
  • Reduced CNS opioid side effectsSafety ProfileModerate
  • Visceral pain reliefAnalgesiaModerate
  • Inflammatory pain reliefAnalgesiaModerate

Contraindications

  • Severe renal impairmentOrganModerateKidney function concerns
  • PregnancyPopulationModeratePotential fetal risk or insufficient safety data
  • Hypersensitivity to kappa-opioid agonistsAllergy/ImmunologyHigh

Adverse Effects

  • Dysphoria (minimal vs central KOR agonists)NeuropsychiatricRare
  • Injection site reactionsLocalUncommon
  • DiuresisRenalCommon
  • NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

  • Other opioidsModerate
  • CNS depressantsLow

Population Constraints

  • Pediatric patientsAgeRelative
  • Elderly patientsAgeRelative
  • Pregnant womenReproductiveRelative
  • Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

  • European UnionInvestigationalResearch compound; no EMA approval.
  • United StatesInvestigationalInvestigated in early-phase clinical trials; no FDA approval.
  • United KingdomInvestigationalResearch compound; no MHRA approval.

CR665 has not received regulatory approval in any jurisdiction. It has been studied in early-phase clinical trials (Phase I/II) as an investigational compound. Development has been associated with Janssen and academic research groups.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack